Suzetrigine is a new non-opioid analgesic recently approved by the FDA. It acts by specifically blocking the Nav1.8 sodium channel, thereby preventing the transmission of pain signals to the brain without causing dependence.<\/p>\n\n\n\n
Dr Anne Marie Pinard, Head of the Chronic Pain Service at CHU de Qu\u00e9bec-Universit\u00e9 Laval and member of the QPRN, highlights the interest of this molecule due to its innovative mechanism of action. She points to the possibility of targeting a specific subunit of sodium channels and administering it in tablet form.<\/p>\n\n\n\n
In clinical trials, suzetrigine proved to be as effective as opioids in relieving certain types of post-operative pain, with fewer side effects and no risk of dependence. Its arrival on the market represents a significant advance in the context of the opioid crisis, although its efficacy against chronic pain remains uncertain.<\/p>\n\n\n\n
Although the drug is approved in the U.S., its arrival in Canada will depend on Health Canada’s assessment.<\/p>\n\n\n\n